Andrew Goodspeed
Overview
Explore the profile of Andrew Goodspeed including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
634
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Goodspeed A, Bodlak A, Duffy A, Nelson-Taylor S, Oike N, Porfilio T, et al.
Clin Cancer Res
. 2025 Mar;
PMID: 40029262
Purpose: Ewing sarcoma (EwS) is the second most common bone cancer in children, accounting for 2% of pediatric cancer diagnoses. Patients who present with metastatic disease at the time of...
2.
Kuo C, Giannikou K, Wang N, Warren M, Goodspeed A, Shillingford N, et al.
bioRxiv
. 2025 Feb;
PMID: 39975230
To date, few studies have detailed the tumor microenvironment (TME) of Ewing sarcoma (EwS). The TME has a vital role in cancer survival and progression with implications in drug resistance...
3.
Steller J, Blue R, Ronca A, Goodspeed A, Powell T, Jansson T
NPJ Microgravity
. 2024 Dec;
10(1):113.
PMID: 39702580
The effects of galactic cosmic radiation on reproductive physiology remain largely unknown. We determined the impact of near-continuous low-dose-rate Californium-252 neutron irradiation (1 mGy/day) as a space-relevant analog on litter...
4.
Mills T, Kain B, Burchill M, Danis E, Lucas E, Culp-Hill R, et al.
Cell Stem Cell
. 2024 Oct;
31(11):1630-1649.e8.
PMID: 39413777
Here, we investigate the contribution of long-term hematopoietic stem cells (HSCs) to trained immunity (TI) in the setting of chronic autoimmune disease. Using a mouse model of systemic lupus erythematosus...
5.
Elias A, Staley A, Fornier M, Vidal G, Alami V, Sams S, et al.
NPJ Breast Cancer
. 2024 Oct;
10(1):88.
PMID: 39368973
Most ER+ breast cancers (BC) express androgen receptors (AR). This randomized phase II trial of 4 months of neoadjuvant fulvestrant (Fulv) alone or with enzalutamide (Combo) assessed whether adding AR...
6.
Kuo L, Crump L, ONeill K, Williams M, Christenson J, Spoelstra N, et al.
Cancer Res Commun
. 2024 Sep;
4(10):2699-2713.
PMID: 39311710
TDO2 is more highly expressed than the nonhomologous TRP-catabolizing enzyme IDO1 in TNBC. We find that TDO2 knockdown can lead to a compensatory increase in IDO1. Therefore, we tested a...
7.
Shirai R, Biebighauser T, Walker D, Oviedo J, Nelson-Taylor S, Bodlak A, et al.
PLoS One
. 2024 Jun;
19(6):e0305490.
PMID: 38875295
Ewing sarcoma is the second most common bone cancer in children, and while patients who present with metastatic disease at the time of diagnosis have a dismal prognosis. Ewing sarcoma...
8.
Chia S, Johnson B, Hu J, Vermeulen R, Chadeau-Hyam M, Guntoro F, et al.
Res Sq
. 2024 Apr;
PMID: 38645169
Breast cancer is the second most common cancer globally. Most deaths from breast cancer are due to metastatic disease which often follows long periods of clinical dormancy. Understanding the mechanisms...
9.
Hawkins H, Yacob B, Brown M, Goldstein B, Arcaroli J, Bagby S, et al.
PLoS One
. 2024 Apr;
19(4):e0298808.
PMID: 38598488
Pancreatic ductal adenocarcinoma (PDAC) presents at advanced stages and is refractory to most treatment modalities. Wnt signaling activation plays a critical role in proliferation and chemotherapeutic resistance. Minimal media conditions,...
10.
Jones R, Scholtes M, Goodspeed A, Akbarzadeh M, Mohapatra S, Feldman L, et al.
Cancer Res
. 2024 Mar;
84(10):1699-1718.
PMID: 38535994
Significance: Targeting NPEPPS, which induces cisplatin resistance by controlling intracellular drug concentrations, is a potential strategy to improve patient responses to platinum-based therapies and lower treatment-associated toxicities.